Researchers at MD Anderson have identified a blood-based biomarker using T cell receptor sequencing that may help assess cancer risk in asymptomatic Lynch syndrome carriers, according to a study in Nature Communications.
PolyBio Research Foundation has launched a $1.35 million program at UCSF to compare and validate diagnostic tests for long COVID, aiming to address the lack of standardized clinical diagnostics in the field.
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
The rapid RT-PCR assay runs on the FINDER platform, establishing it as a molecular point-of-care platform with multifunctional capabilities.
The NIH has awarded $850,000 to Northwell Health’s Feinstein Institutes to advance a noninvasive menstrual blood test for endometriosis, aiming to reduce reliance on surgical diagnosis, according to the institutes.
Researchers at JAX and MIT have developed a microneedle patch that samples immune cells from skin within hours, providing a noninvasive alternative to blood draws and biopsies.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
BRAINBox Solutions reports near-completion of its HeadSMART II trial for a concussion blood test, supporting an upcoming FDA submission, and advances in a point-of-care biomarker collaboration with Prolight Diagnostics.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter, vignette-based study found that adding a rapid sepsis test result to standard clinical data changed or reinforced diagnostic decisions in 86% of cases.